MARKET

LSTA

LSTA

Lisata Therapeutics Inc
NASDAQ
2.960
-0.210
-6.62%
Closed 16:00 05/24 EDT
OPEN
3.053
PREV CLOSE
3.170
HIGH
3.190
LOW
2.890
VOLUME
18.35K
TURNOVER
0
52 WEEK HIGH
4.533
52 WEEK LOW
1.950
MARKET CAP
24.59M
P/E (TTM)
-1.2040
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LSTA last week (0520-0524)?
Weekly Report · 11h ago
Lisata Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
Buy Rating on Lisata Therapeutics Backed by Regulatory Milestones and Promising Study Progress
TipRanks · 6d ago
Health Care Sector Update for 05/20/2024: ENSC, LSTA, HIMS, NKGN, NVO, LLY
NASDAQ · 05/20 19:58
EMa Grants Lisata Therapeutics Paediatric Investigation Plan Waiver For Certepetide In Pancreatic Cancer
Benzinga · 05/20 12:31
LISATA THERAPEUTICS RECEIVES PAEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY FOR CERTEPETIDE IN PANCREATIC CANCER
Reuters · 05/20 12:30
LISATA THERAPEUTICS INC - WAIVER CONFIRMS THAT PAEDIATRIC STUDIES OF CERTEPETIDE IN PANCREATIC CANCER ARE NOT NEEDED
Reuters · 05/20 12:30
Weekly Report: what happened at LSTA last week (0513-0517)?
Weekly Report · 05/20 10:32
More
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Webull offers Lisata Therapeutics Inc stock information, including NASDAQ: LSTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LSTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LSTA stock methods without spending real money on the virtual paper trading platform.